Dr Danielle Borg

BAppSci (Hons) PhD

Project Coordinator

Projects

Il-22 therapy for Type 2 Diabetes

Currently involved in a New Approach to Treating Type 2 Diabetes, a TRI based research project.

AGEs as a contributor to Type 1 Diabetes

Modulation of AGE cellular receptors in pancreatic beta cell function

Maternal transfer of glycated proteins

Biomarker assay development for families at high risk of developing Type 1 Diabetes

Advanced glycation as an environmental factor for type 1 diabetes

About me

Danielle is the program coordinator for the QLD family cohort study at the Mater Research Institute. Her passion in medical research was sparked during her PhD in type 1 diabetes with a leading immunologist in Germany, at the Centre for Regenerative Therapies, Technische Universität Dresden. Her interest in chronic disease continued in Australia into type 2 diabetes with world-renowned, highly-cited biochemists and immunologists. She has over 10 years of research experience in the fields of Diabetes, Cell Transplantation, Cell Imaging and Biochemistry. Throughout her research career, she published peer-reviewed publications, obtained funding for projects, and enjoyed the collaborative nature of medical research.

Danielle’s interest lies in improving health outcomes to the community via the translation of innovative findings from basic and clinical research. This overarching interest prompted her move to clinical research and study coordination after the birth of her first child. She thrives on scientific communication and is an avid believer in giving back to the wider scientific community sitting on numerous committees, grant reviewing and volunteering for several organisations. Danielle is excited to be a part of the cohort study which will put QLD, her home state, on the map nationally for birth cohort studies.

Publications

  1. Danielle Borg*, Felicia Yap*, Sahar Keshvari, David G Simmons, Linda Gallo, Amelia Fotheringham, Aowen Zhuang, Robyn Slattery, Sumaira Z Hasnain, Melinda Coughlan, Phillip Kantharidis & Josephine Forbes, Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction, Islets, 2018, 10(1): 10-24.
  2. Margeret C. Hardy, Mathilde R. Desselle, and the 2016 Catch a Rising Star Consortium., Engaging rural Australian communities in National Science Week helps increase visibility for women researchers., Royal Society Open Science, 2017, 4: 170548.
  3. Micheal Ward, Nicole Flemming, Linda Gallo, Amelia Fotheringham, Domenica McCarthy, Aowen Zhuang, Peter Tang, Danielle Borg, Hannah Shaw, Benjamin Harvie, David Briskey, Llion Roberts, Manuel Plan, Michael Murphy, Mark Hodson and Josephine Forbes, Targeted mitochondrial therapy, using MitoQ, shows equivalent renoprotection to angiotensin converting enzyme inhibition in experimental type 2 diabetes. Scientific Reports, 2017, 7, 15190.
  4. Borg, D.J., Wang, R., Murray, L., Tong, H., Steptoe, R., McGuckin, M., Hasnain, S., The effect of inteleukin-22 on autoimmune diabetes in the NOD mouse, Diabetologia, 2017, 60: 2256.
  5. Leung, S., Forbes, J.M.*, and Borg, D.J.*, Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis, Current Diabetes Reports, 2016,16(10): 100.
  6. Danielle J. Borg*, Petra B. Welzel*, Milauscha Grimmer, Jens Friedrichs, Marc Weigelt, Carmen Wilhelm, Marina Prewitz, Aline Stißel, Angela Hommel, Thomas Kurth, Uwe Freudenberg, Ezio Bonifacio, Carsten Werner, Macroporous biohybrid cryogels for co-housing pancreatic islets with mesenchymal stromal cells, Acta Biomateralia, 2016, 15;44: 178-87.
  7. Borg, D.J and Forbes, J.M, Targeting advanced glycation with pharmaceutical agents: where are we now? Glycoconjugate Journal. 2016, 33(4): 653-70.
  8. Gallo LA, Ward MS, Fotheringham AK, Zhuang A, Borg DJ, Flemming NB, Harvie BM, Kinneally TL, Yeh SM, McCarthy DA, Koepsell H, Vallon V, Pollock C, Panchapakesan U, Forbes JM. Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports. 2016; 6: 26428
  9. Coleman MA, Jessup CF, Bridge JA, Overgaard NH, Penko D, Walters S, Borg DJ, Galea R, Forbes JM, Thomas R, Coates PT, Grey ST, Wells JW, Steptoe RJ. Antigen-encoding bone marrow terminates islet-directed memory CD8+ T-cell responses to alleviate islet transplant rejection. Diabetes. 2016; 65(5): 1328-40.
  10. Salonen, K.M, Ryhaenen, S.J., Forbes, J.M., Borg, D.J., Haekoenen, T., Ilonen, J., Simell, O., Veijola, R., Groop, P-H., Knip, M., Decrease in Circulating Concentrations of Soluble Receptors for Advanced Glycation End Products at the Time of Seroconversion to Autoantibody Positivity in Prediabetic Children. Diabetes Care, 2015; 38(4):665-70.
  11. Hasnain, S.Z., Borg, D.J., Harcourt, B., Tong, H., NG, C. P., Das, I., Wang, R., Chen, A.C-H., Forbes, J.M., Whitehead, J.P., Prins, J.B. and McGuckin, M.A., IL-22 is an endogenous suppressor of β-cell oxidative and endoplasmic reticulum stress that restores glycemic control in diabetes. Nature Medicine, 2014; 20: 1417-26.
  12. Tesch, G., Sourris, K.C., Summers. S.A., McCarthy, D., Ward, M.S., Borg. D.J., Gallo, L.A., Fotheringham, A.K., Pettit, A., Yap, F.Y.T., Harcourt, B.E., Tan, L.Y., Kausman, J.Y., Nikolic-Paterson, D., Kitching, A.R and Forbes, J.M. Deletion of bone marrow-derived receptor for advanced glycation end products (RAGE) improves renal function in an experimental model of diabetes. Diabetologia, 2014; 57(9): 1977-85.
  13. Borg, D.J., Weigelt, M, Wilhelm, C., Gerlach, M., Bickle, M., Speier, S., Bonifacio, E. and Hommel, A, Mesenchymal stromal cells improve transplanted islet survival and islet function in a syngeneic mouse model. Diabetologia, 2014; 57(3): 522-31.
  14. Borg, D.J and Bonifacio, E., The use of biomaterials in islet transplantation. Current Diabetes Reports, 2011; 11(5): 434-444.
  15. Sordi, V., Melzi, R., Mercalli, A., Formicola, R., Doglioni, C., Tiboni, F., Ferrari, G., Nano, R., Chwalek, K., Borg, D., Lammert, E., Bonifacio, E. and Piemonti, L., Mesenchymal Cells Appearing in Pancreatic Tissue Culture Are Bone Marrow-Derived Stem Cells With the Capacity to Improve Transplanted Islet Function, Stem Cells, 2010; 28(1): 140-151.
  16. Borg, D.J., Dawson, R.A., Leavesley, D.I., Hutmacher, D.W., Upton, Z. and Malda, J., Functional and phenotypic characterization of human keratinocytes expanded in microcarrier culture, J. of Biomed. Materials Res. Part A, 2009; 88A (1): 184-194.

Research fields

Diabetes, Biomaterials, AGEs, Pregnancy and Development, Chronic Disease